© The Financial Times Ltd 2016 FT and 'Financial Times' are trademarks of The Financial Times Ltd.
As of Feb 06, 2016, the consensus forecast amongst 30 polled investment analysts covering GlaxoSmithKline plc advises investors to hold their position in the company. This has been the consensus forecast since the sentiment of investment analysts deteriorated on Feb 21, 2013. The previous consensus forecast advised that GlaxoSmithKline plc would outperform the market.
|Last year||3 months ago||2 months ago||4 weeks ago||Latest|
The 24 analysts offering 12 month price targets for GlaxoSmithKline plc have a median target of 1,485, with a high estimate of 1,800 and a low estimate of 1,250. The median estimate represents a 9.27% increase from the last price of 1,359. View Full Financials
In 2015, GlaxoSmithKline PLC reported a dividend of 0.80 GBP, equaling last years dividend. The 24 analysts covering the company expect dividends of 0.82 GBP for the upcoming fiscal year, an increase of 2.50%. View Full Financials
|Div growth (TTM)||0.00%|
On Feb 03, 2016, GlaxoSmithKline plc reported 4th quarter 2015 earnings of 0.181 per share. This result was in line with the consensus of the 12 analysts following the company and under-performed last year's 4th quarter results by 15.81 %.
The next earnings announcement is expected on Apr 27, 2016. View Full Interim Financials
|Average growth rate||-1.97 %|
GlaxoSmithKline plc reported annual 2015 earnings of 0.757 per share on Feb 03, 2016. View Full Annual Financials
|Average growth rate||-9.56 %|
GlaxoSmithKline plc had 4th quarter 2015 revenues of 6.286bn. This bettered the 6.256bn consensus of the 11 analysts covering the company. This was 1.62% above the prior year's 4th quarter results. View Full Interim Financials
|Average growth rate||+0.57 %|
GlaxoSmithKline plc had revenues for the full year 2015 of 23.923bn. This was 3.99% above the prior year's results. View Full Annual Financials
|Average growth rate||-3.11 %|